Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382106 · ClinicalTrials.gov registry record · Phase 4
Smoking Cessation and Functional CT Assessment
A Phase 4 study, sponsored by Eric A. Hoffman.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT03382106: Completed Phase 4 study, sponsored by Eric A. Hoffman.
NCT03382106 is a Phase 4 study that has completed, run by Eric A. Hoffman. The registered enrollment target is 162 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03382106, a Phase 4 study, has completed, sponsored by Eric A. Hoffman.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.
Primary Outcome
Our outcome measure is the change in regional blood volume between baseline and interventions with CT imaging, sildenafil/placebo and smoking cessation.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Sildenafil 20 MG
- DIAGNOSTIC_TEST Pulse wave velocity
- DIAGNOSTIC_TEST Carotid artery compliance and stiffness
- DIAGNOSTIC_TEST Pressure wave reflection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2024-09-24 |
| Phase | Phase 4 |
What the finished NCT03382106 record still lists
NCT03382106 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo Oral Tablet is the first listed.
NCT03382106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03382106 about?
NCT03382106 is a clinical study titled "Smoking Cessation and Functional CT Assessment". The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.
What is the current status of trial NCT03382106?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2018-03-19. Estimated completion is 2024-09-24.
What interventions are being tested in trial NCT03382106?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Sildenafil 20 MG (DRUG), Pulse wave velocity (DIAGNOSTIC_TEST), Carotid artery compliance and stiffness (DIAGNOSTIC_TEST), Pressure wave reflection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03382106?
This trial is sponsored by Eric A. Hoffman, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03382106's enrollment target sits among peer trials
162 503rd of 2000 higher than 1,495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI